Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition

被引：16
|
作者：
Musunuru, Kiran [1 ]
机构：
[1] Univ Penn, Cardiovasc Inst, Dept Med, Dept Genet,Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 | 2021年 / 72卷
关键词：
cholesterol; coronary artery disease; genetics; inflammation; lipoproteins; triglycerides; OF-FUNCTION MUTATIONS; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN CHOLESTEROL; TRIGLYCERIDE TRANSFER PROTEIN; HIGH-RISK; CARDIOVASCULAR-DISEASE; HEART-DISEASE; DOUBLE-BLIND; TARGETING APOLIPOPROTEIN(A); MENDELIAN RANDOMIZATION;
D O I：
10.1146/annurev-med-080819-044918
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Statins, ezetimibe, and PCSK9 inhibitors are currently the standard of care for the prevention and treatment of coronary artery disease. Despite their widespread use, coronary artery disease remains the leading cause of death worldwide, a fact that pleads for the development of new protective therapies. In no small part due to advances in the field of human genetics, many new therapies targeting various lipid traits or inflammation have recently received approval from regulatory agencies such as the US Food and Drug Administration or fared favorably in clinical trials. This wave of new therapies promises to transform the care of patients at risk for life-threatening coronary events.
引用
收藏
页码：447 / 458
页数：12
相关论文
共 50 条
  • [41] Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection
    Luscher, Thomas F.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (48) : 3545 - 3548
  • [42] Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese
    Daisuke Nose
    Yuhei Shiga
    Yoko Ueda
    Yoshiaki Idemoto
    Kohei Tashiro
    Yasusnori Suematsu
    Takashi Kuwano
    Ken Kitajima
    Keijiro Saku
    Shin-ichiro Miura
    [J]. Heart and Vessels, 2019, 34 : 29 - 32
  • [43] PCSK9 inhibitors for treating familial hypercholesterolaemia
    Hiroshi Mabuchi
    Atsushi Nohara
    [J]. Nature Reviews Endocrinology, 2015, 11 : 8 - 9
  • [44] Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
    Page, Michael M.
    Watts, Gerald F.
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (02) : 299 - 312
  • [45] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    [J]. REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
  • [46] PCSK9 inhibition 2018: riding a new wave of coronary prevention
    Ward, Natalie C.
    Page, Michael M.
    Watts, Gerald F.
    [J]. CLINICAL SCIENCE, 2019, 133 (02) : 205 - 224
  • [47] Statins and Their Effect on PCSK9—Impact and Clinical Relevance
    Beth A. Taylor
    Paul D. Thompson
    [J]. Current Atherosclerosis Reports, 2016, 18
  • [48] PCSK9 inhibition in patients with hypercholesterolemia
    Desai, Nihar R.
    Sabatine, Marc S.
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 567 - 574
  • [49] PCSK9 Inhibition and Oxidized Phospholipids
    Bhatia, Harpreet S.
    Yeang, Calvin
    Baruch, Amos
    Yang, Xiaohong
    Stroes, Erik S. G.
    Tsimikas, Sotirios
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (12) : 1288 - 1289
  • [50] New prospects for PCSK9 inhibition?
    Landmesser, Ulf
    Chapman, M. John
    Stock, Jane K.
    Amarenco, Pierre
    Belch, Jill J. F.
    Boren, Jan
    Farnier, Michel
    Ference, Brian A.
    Gielen, Stephan
    Graham, Ian
    Grobbee, Diederick E.
    Hovingh, G. Kees
    Luscher, Thomas F.
    Piepoli, Massimo F.
    Ray, Kausik K.
    Stroes, Erik S.
    Wiklund, Olov
    Windecker, Stephan
    Luis Zamorano, Jose
    Pinto, Fausto
    Tokgozoglu, Lale
    Bax, Jeroen J.
    Catapano, Alberico L.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2600 - 2601
12345